Mexico Could Make History by Treating CBD Like a Supplement, as It Should

Mexico legalized medicinal marijuana in 2017, opening the door to the cultivation, production and use of cannabis products for medical use, provided the tetrahydrocannabinol (THC) in the cannabis is less than 1 percent. Proponents of the law believe it paves the way for making cannabidiol (CBD) as common and accessible as a vitamin supplement. However, as Forbes points out, pharmaceutical companies may try to stop access to it by trying to get CBD classified as a medicine.

It’s obvious Mexico is way ahead of the U.S. when it comes to recognizing the medicinal uses of CBD. To date, science has shown that cannabinoid receptors in your body play an important role in many body processes, including metabolic regulation, cravings, pain, anxiety, bone growth, and immune function. And CBD has shown marked results in prompting those receptors for help in fighting:

  • Mood disorders
  • Degenerative neurological disorders such as dystonia
  • Multiple sclerosis
  • Tumors
  • Parkinson's disease
  • Post-traumatic stress disorder (PTSD)
  • Seizures

CBD also works as an excellent painkiller and works well in treating anxiety issues. Cannabis oil applied topically has been proven to heal sunburn overnight.

Yet, the U.S. federal government continues to classify it as a Schedule 1 drug, right up there with heroin, LSD and ecstasy. States, in turn, have defiantly been enacting medical marijuana laws, putting users who legally use medicinal cannabis in those states in danger of being federal criminals, regardless. The fact is it’s time for a change, Forbes says.

Forbes also correctly predicts the marketing roadblocks that Big Pharma will put up as CBD becomes more common — as GW Pharmaceuticals already has done in the U.S. with their pharmaceutical grade CBD. The thing is, as Mexico’s president and Forbes point out, you can’t patent a botanical product, which means GW most certainly has changed or adulterated their product in some way in order to make it patentable.

You need look no further than the drug company’s clinical trials to see the differences between pure CBD and the pharma product. While regular medical cannabis is typically well-tolerated, with few side effects, a whopping 93 percent of children in the company’s CBD group — as well as 75 percent of those in the placebo group — suffered adverse events in this trial. Of course, there’s always the possibility that “pharmaceutical strength” CBD might be too pure, hence the high rate of side effects.

But regardless, there’s a significant difference in cost between a CBD drug and natural CBD oil, which in and of itself is of great concern for many patients and their families who now worry Big Pharma is trying to take over the cannabis industry. Perhaps Forbes is right — it may very well be time for the U.S. to follow Mexico’s lead before the drug companies take total control north of the border.

Click Here and be the first to comment on this article
Post your comment